Kublin Lab

Kublin Lab

The Kublin lab

Our Research

Welcome to the Kublin Lab. We study the role of the microbiome in vaccine responses, and focus on how specific microbes and their metabolites modulate host innate and adaptive immune responses. Our work includes developing discrete microbial consortia to manipulate vaccine responses in gnotobiotic mouse models, as well as investigating microbiome and immunogenicity data from HIV, malaria, and TB clinical trials.


Current Opinion in HIV and AIDS 2018

Utilizing gnotobiotic models to inform the role of the microbiome in vaccine response heterogeneity.  Cram JA, Hager KW, Kublin JG. 

The Journal of Infectious Diseases 2017

A randomized trial of the prophylactic activity of DSM265 against pre-erythrocytic Plasmodium falciparum controlled human malaria infection by mosquito bites and direct venous inoculation. Murphy SC, Duke ER, Shipman KJ, Jensen RL, Fong Y, Ferguson S, Janes HE, Gillespie K, Seilie AM, Hanron AE, Rinn L, Fishbaugher M, VonGoedert T, Fritzen E, Kappe SH, Chang M, Sousa JC, Marcsisin SR, Chalon S, Duparc S, Kerr N, Möhrle JJ, Andenmatten N, Rueckle T, Kublin JG.

Science Translational Medicine 2017

Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, VonGoedert T, Firat M, Magee S, Fritzen E, Betz W, Kain HS, Dankwa DA, Steel RW, Vaughan AM, Noah Sather D, Murphy SC, Kappe SH. 


Latest News

Enlisting the microbiome in the quest for an AIDS vaccine

Hutch News | Sabin Russell | Nov. 22, 2017
We now know that microbial communities, especially in our guts, profoundly affect immune response.

GMO malaria saves the day

Science Spotlight | BL DeBuysscher | Feb. 20, 2017
Researchers from the Kublin lab at Fred Hutch, UW and Seattle Biomedical Research Institutes are using genetic engineering to create a new genetically attenuated parasite (GAP) vaccine candidate. 

On the path to a new-generation malaria vaccine

Hutch News | Mary Engel | Jan. 4, 2017
New approach using genetically modified parasite ‘primes the immune system’ in first human trial.